Cancer-Associated Venous Thromboembolic Disease, Version 1.2015

View More View Less
  • 1 The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Moffitt Cancer Center; Mayo Clinic Cancer Center; University of Michigan Comprehensive Cancer Center; St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; Dana-Farber/Brigham and Women's Cancer Center; National Blood Clot Alliance; Massachusetts General Hospital Cancer Center; The University of Texas MD Anderson Cancer Center; University of Washington/Seattle Cancer Care Alliance; Yale Cancer Center/Smilow Cancer Hospital; Stanford Cancer Institute; Roswell Park Cancer Institute; Fox Chase Cancer Center; Vanderbilt-Ingram Cancer Center; Duke Cancer Institute; University of Alabama at Birmingham Comprehensive Cancer Center; UC San Diego Moores Cancer Center; City of Hope Comprehensive Cancer Center; Huntsman Cancer Institute at the University of Utah; Memorial Sloan Kettering Cancer Center; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; Fred & Pamela Buffett Cancer Center; Robert H. Lurie Comprehensive Cancer Center of Northwestern University; and National Comprehensive Cancer Network
Restricted access

The NCCN Guidelines for Cancer-Associated Venous Thromboembolic Disease outline strategies for treatment and prevention of venous thromboembolism (VTE) in adult patients with a diagnosis of cancer or for whom cancer is clinically suspected. VTE is a common complication in patients with cancer, which places them at greater risk for morbidity and mortality. Therefore, risk-appropriate prophylaxis is an essential component for the optimal care of inpatients and outpatients with cancer. Critical to meeting this goal is ensuring that patients get the most effective medication in the correct dose. Body weight has a significant impact on blood volume and drug clearance. Because obesity is a common health problem in industrialized societies, cancer care providers are increasingly likely to treat obese patients in their practice. Obesity is a risk factor common to VTE and many cancers, and may also impact the anticoagulant dose needed for safe and effective prophylaxis. These NCCN Guidelines Insights summarize the data supporting new dosing recommendations for VTE prophylaxis in obese patients with cancer.

Provided content development and/or authorship assistance.

Supplementary Materials

    • Supplemental Material (PDF 168 KB)
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 926 650 41
PDF Downloads 262 200 22
EPUB Downloads 0 0 0